OpenAI Expands Globally with First Overseas AI Lab in Singapore 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Goldman Sachs Sees Stronger U.S. Dollar as Global Economic Gaps Widen 
NHS shakeup: if it sounds like we’ve been here before, it’s because we have 
Asian Stocks Slide Ahead of Nvidia Earnings as Tech Shares Tumble 
Gold Prices Slip as Iran Conflict and Fed Rate Hike Fears Weigh on Market Sentiment 
Texas Sues Meta Over WhatsApp Encryption Claims 
SoftBank Shares Surge as OpenAI IPO Buzz and SB Energy Filing Boost AI Optimism 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
Moody’s Downgrades Mexico Credit Rating Amid Rising Debt and Fiscal Pressure 
Stellantis CEO Antonio Filosa to Reveal Turnaround Strategy Focused on U.S. Sales and China Partnerships 
GameStop Raises eBay Stake to 6.6% as Ryan Cohen Pushes $56 Billion Takeover Bid 
X Corp Loses Legal Battle Over Australia Child Safety Fine 
Nvidia Beats Earnings Expectations as AI Demand Drives Record Growth 
Lam Research Expands AI-Powered Semiconductor Tools and Arizona Operations 
SpaceX Starship V3 Test Flight Boosts IPO Momentum Ahead of Historic Market Debut 
US Stock Futures Slip as Nvidia Earnings Fail to Fully Impress Investors 
Samsung Biologics Co. is adding a new plant to its portfolio, and it will be its fifth facility for Contract Development and Manufacturing Organization (CDMO) deals. The South Korean biotech firm is building its newest plant in Songdo, Incheon, where it is currently headquartered.
According to The Korea Economic Daily, once Samsung Biologics completes the construction of the CDMO factory, its total production capacity will increase to 800,000 liters per year. The company is investing KRW1 trillion or $762.2 million for this project in South Korea.
It was noted that the company is making a fast follow-up with its investment since the fourth plant is also under construction. This factory has been dubbed the largest single biomanufacturing facility in the world, and construction is currently in full swing.
Samsung Group’s biotech arm confirmed the construction of its new Songdo plant late last week during its board meeting. It will soon rise on the second bio campus in the region’s free economic zone located west of Seoul. Prior to this announcement, Samsung Biologics already said in July of last year that it would allot KRW7.5 trillion to set up the campus by the year 2032.
In any case, the fifth plant will be the first one to be constructed on the second bio campus. While the third plant was built with just a KRW850 trillion budget, it is said to have a similar production capacity as the fifth factory. Sources said that the latest facility costs more because it will be constructed on a greenfield.
Korea Joongang Daily reported that Samsung Biologics would break ground for its fifth plant soon, and it is expected to be completed by September 2025. It will sit on a 96,000 square meter lot inside the Bio Campus II.
The company is expanding to take advantage of the current steady growth in demand for medical treatments. Finally, Samsung Biologics is taking this aggressive step of further building up its production facilities to cement its leadership in the global CDMO market.
“Amid the steady global demands for biopharmaceuticals, outsourcing of biomedical products is on the rise since the Covid-19 outbreak,” John Rim, Samsung Biologics’ chief executive officer, commented. “Preemptive investment is needed in order to continue our leadership in the market after the fourth plant.”
